Children with metabolic dysfunction-associated steatotic liver disease (MASLD), a form of fatty liver disease, are more than 40 times more likely to die than…
Fatty liver disease
FATTY LIVER DISEASE
ColumnsLiver medication can be expensive, but it doesn’t have to be
Every month, I receive deliveries of my medications, most of them for my metabolic-associated steatohepatitis (MASH), a fatty liver disease. I probably don’t need…
FATTY LIVER DISEASE
NewsFDA, Health Canada reviewing semaglutide for liver disease MASH
The U.S. Food and Drug Administration and Health Canada are reviewing Novo Nordisk‘s requests to approve semaglutide’s under-the-skin formulation, at a dose of 2.4…
FATTY LIVER DISEASE
NewsMET gene mutations could be rare cause of MASLD, MASH
Rare mutations in the MET gene can cause metabolic dysfunction-associated steatotic liver disease (MASLD), a form of fatty liver disease, a study found. After…
FATTY LIVER DISEASE
ColumnsHow clay sculpting helps me cope with my MASH diagnosis
The first time I ever held a ball of clay — OK, it was probably Play-Doh — I felt a strong connection to creating things…
FATTY LIVER DISEASE
NewsAmerican Liver Foundation gears up for advocacy summit
Patients, caregivers, and supporters will head to Washington later this month to advocate for policies to improve life for people living with fatty liver…
Supporters are gearing up for World Liver Day on April 19 — marked by a global campaign to raise awareness about liver health and…
FATTY LIVER DISEASE
ColumnsManaging the itching associated with fatty liver disease
One thing I used to look forward to every spring was the end of my dry skin — a result of winter’s harsh rebuke of…
FATTY LIVER DISEASE
NewsGLP-1 agonists linked to lower risk of complications in MASLD, MASH
Use of glucagon-like peptide-1 (GLP-1) receptor agonists in people with metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH) — forms of…
FATTY LIVER DISEASE
NewsPhase 3 trial of lanifibranor for MASH completes enrollment
Enrollment is complete for a Phase 3 clinical trial testing lanifibranor in people with metabolic dysfunction-associated steatohepatitis (MASH) — a severe type of fatty…
Recent Posts
- My child with Alagille syndrome is going through a ‘picky eater’ phase
- Biliary atresia treatment AX-0810 faring well in early testing
- Clinical trial results support bepirovirsen for hepatitis B
- Vitamin D may help protect against liver damage in those with PBC: Study
- Think smoking only affects your lungs? Your liver would like a word.